PF-Atlas › Clinical Trials › NCT05195918
Study of Oral Epigallocatechin-3-gallate in IPF Patients
EGCG 300 mg + Nintedanib · Phase 1
Registry ID
NCT05195918
Phase
Phase 1
Status
Completed
Drug / intervention
EGCG 300 mg + Nintedanib
Sponsor
Hal Chapman
Start
2023-08-24
Enrollment
50
Locations
7
About this trial
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05195918 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.